Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition)

BACKGROUND: Cangrelor is an intravenous P2Y(12) inhibitor approved to reduce periprocedural ischemic events in patients undergoing percutaneous coronary intervention not pretreated with a P2Y(12) inhibitor. METHODS: A total of 11 145 patients were randomized to cangrelor or clopidogrel in the CHAMPI...

Descripción completa

Detalles Bibliográficos
Autores principales: Cavender, Matthew A., Bhatt, Deepak L., Stone, Gregg W., White, Harvey D., Steg, Ph. Gabriel, Gibson, C. Michael, Hamm, Christian W., Price, Matthew J., Leonardi, Sergio, Prats, Jayne, Deliargyris, Efthymios N., Mahaffey, Kenneth W., Harrington, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2016
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5006794/
https://www.ncbi.nlm.nih.gov/pubmed/27482008
http://dx.doi.org/10.1161/CIRCULATIONAHA.115.020829

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5006794/
https://www.ncbi.nlm.nih.gov/pubmed/27482008
http://dx.doi.org/10.1161/CIRCULATIONAHA.115.020829

Ejemplares similares